/Does belimumab treatment improve overall SLE disease activity across multiple organ domains, including musculoskeletal and mucocutaneous domains, and reduce worsening in haematological, immunological, and renal domains?
Research Question
Does belimumab treatment improve overall SLE disease activity across multiple organ domains, including musculoskeletal and mucocutaneous domains, and reduce worsening in haematological, immunological, and renal domains?
2026